Prostate cancer drug now available to more patients with aggressive form of disease
A newly expanded prostate cancer drug could bring new hope to patients with a common form of the disease.
Novartis, a Switzerland-based pharmaceutical company, announced on March 28 that the U.S. Food and Drug Administration (FDA) has expanded approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan), a targeted radioligand therapy (RLT) that is given before chemotherapy.
(RLTs are a form of targeted nuclear medicine that doctors use to treat multiple types of cancer, according to Novartis.)
Prostate Cancer Risk Increases By 45% Among Men Who Share One Troubling Behavior
The drug is intended for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have received one round of androgen receptor pathway inhibitors (ARPIs), a class of drugs used in the treatment of metastatic prostate cancer.
Pluvicto first got FDA approval on March 23, 2022, but this new expanded approval triples the number of patients eligible to receive the drug, according to a Novartis press release.
Read On The Fox News App
The drug is administered through an IV into the bloodstream, where it attaches to prostate cancer cells and either keeps them from replicating or kills them.
Prostate Cancer Cases Spike In This Us State As Doctors Share Likely Reason
"The earlier indication for Pluvicto could really change our treatment paradigms for patients with mCRPC," said lead study author Michael Morris, MD, prostate cancer section head at Memorial Sloan Kettering Cancer Center in New York.
"It offers a targeted therapy that better delays disease progression compared to a second ARPI. This approval is a significant step forward and should open the doorway to a therapy that has clear clinical advantages for the patient with mCRPC who has progressed on one ARPI and has not received chemotherapy."
This is a form of prostate cancer that has spread to other parts of the body and does not respond to standard hormone therapy, according to WebMD.
It also has high levels of prostate-specific membrane antigen (PSMA), a protein produced by prostate cancer cells.
In clinical trials, Pluvicto "significantly reduced the risk of progression or death" by 59% in mCRPC patients, Novartis reported.
IMAGE
"The FDA's expanded approval of [lutetium Lu 177 vipivotide tetraxetan] marks a transformative step forward in the treatment of mCRPC, underscoring the growing impact of precision oncology," Jorge A. Garcia, MD, a genitourinary medical oncologist and chair of the Solid Tumor Oncology Division at University Hospitals Seidman Cancer Center/Case Western Reserve University in Cleveland, Ohio, told OncLive.
"By enabling access to this targeted radioligand therapy prior to chemotherapy, we are not only broadening treatment options, but also redefining the standard of care for PSMA-positive disease."
Prostate cancer is the second leading cause of death among men; mCRPC makes up a majority of the deaths and 20% of all metastatic prostate cancer cases.
Studies have shown that approximately 10% to 20% of patients with prostate cancer develop mCRPC within five years of follow-up after initial therapy, and cases of metastatic patients have risen 4% to 5% each year since 2011.
Click Here To Sign Up For Our Health Newsletter
Sixty percent of prostate cancers are diagnosed in men who are 65 or older, according to the American Cancer Society. The risk of being diagnosed with metastatic prostate cancer typically occurs between 65 and 74.
Adverse effects of Pluvicto included dry mouth (61%), fatigue (53%), nausea (32%) and constipation (22%), the release stated.
The patients receiving the drug were able to proceed with chemotherapy after taking it.
Novartis is committed to delivering Pluvicto to the nearly 600 RLT treatment sites in the U.S., the company stated.
For more Health articles, visit www.foxnews.com/health
Looking ahead, Novartis said it plans to investigate the use of RLTs for other types of advanced cancers, including breast, colon, neuroendocrine, lung and pancreatic cancers.Original article source: Prostate cancer drug now available to more patients with aggressive form of disease
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Delta warns new tariffs could force it to stop buying foreign-made airplanes
WASHINGTON (Reuters) -Delta Air Lines warned new tariffs on imported airplanes and parts could force the airline to stop buying foreign-made planes impacting millions of customers. The Atlanta-based carrier told the U.S. Commerce Department in comments seen by Reuters Thursday that in 2023 and 2024 it took delivery of 47 Airbus aircraft produced in Canada, Germany and France. If the carrier had not been able to take delivery of those planes because of tariffs it would have forced flight cancellations impacting 10 million customers. Delta said a "similar impact could be expected going forward" if the Trump administration imposes new tariffs.
Yahoo
20 minutes ago
- Yahoo
Dr. Martens' Stock Soars as CEO Implements New Strategic Plan Following ‘Year of Stabilization'
Shares for Dr. Martens Plc surged nearly 24 percent on Thursday following the release of a new strategic turnaround plan in efforts to return to profit growth in fiscal 2026. According to chief executive officer Ije Nwokorie, who took the helm earlier this year, the company's 'single focus' in fiscal 2025 was to bring stability back to Dr. Martens. More from WWD Journeys Helps Genesco Deliver Q1 Sales Above Expectations Dr. Martens Looks to Adidas For New Chief Brand Officer Name Game: Shoe Carnival Is Converting More Stores to Shoe Station Banner 'We have achieved this by returning our direct-to-consumer channel in the Americas back to growth, resetting our marketing approach to focus relentlessly on our products, delivering cost savings, and significantly strengthening our balance sheet,' Nwokorie said in a statement. In fiscal 2025, the UK-based footwear company reported that net revenue fell 10 percent to 787.6 million pounds from 877.1 million in fiscal 2024. Dr. Martens noted that the results were in-line with guidance, however, and came up against a challenging macroeconomic and consumer backdrop in several of its core markets. Net debt for the year was 249.5 million pounds, down from 359.8 million pounds in fiscal 2024. Net profit stood at 4.5 million pounds in the year to the end of March, down from 69.2 million pounds the year prior. By category, overall, pairs were down 9 percent, with DTC pairs flat and wholesale pairs down 15 percent as expected, as the company's wholesale partners normalized their inventory levels. 'We saw a very strong performance in shoes, with DTC pairs up 15 percent with particular success in our bestselling Adrian loafer, as well as in new shoe families, the Lowell and Buzz,' the company said in its latest earnings statement. 'Sandals also saw a good performance, with DTC pairs up 7 percent, and we continue to see a strong performance in our mules range, led by the Zebzag. Boots remained challenging, with DTC pairs down 9 percent, with our continuity boots weaker, as expected. This was partially offset by success in product newness, both as extensions of the core icons, for example through the Ambassador soft leather boot and through new product lines such as the Anistone biker boot.' As a proportion of fiscal year 2025 Group revenue, boots accounted for 57 percent, shoes 26 percent, sandals 12 percent and bags & other 5 percent. By channel, direct-to-consumer revenue was down 4.2 percent to 510.7 million pounds in fiscal 2025, while wholesale fell 19.5 percent to 276.9 million pounds, as expected. Within DTC, retail revenue was down 5.6 percent to 242.4 million pounds and e-commerce was down 2.9 percent to 268.3 million pounds. By region, EMEA revenue was down 11.0 percent to 384.2 million pounds for the year, which was driven by the UK. In the Americas, revenue was down 11.4 percent to 288.5 million pounds, and in APAC, revenue dipped 3.8 percent to 114.9 million pounds, with a good performance in Japan and China, the company noted. Looking closer at the Americas, Dr. Martens stated that the region delivered DTC growth in the second half of fiscal 2025 as the company pivoted its marketing to 'relentlessly focus' on product. 'With new products such as Ambassador, Anistone, Buzz and Dunnet Flower performing very strongly for us and our partners; we delivered 25 million pounds of annualized cost savings, at the top end of our target, with the full benefit in fiscal 2026; and we strengthened our balance sheet through a significant reduction in inventory and net debt, as well as the successful refinancing of the Group,' the company said. As for tariffs, the company noted that the entirety of its spring/summer 2025 stock is already in the market, and by the start of July, the majority of autumn/winter 2025 will be either in the market or in transit. 'We generate strong product gross margins, which is helpful given that tariffs are charged on cost, not retail price,' the company stated. 'We will continue to assess the situation carefully, but can confirm that for SS25 and AW25 we will be keeping average prices unchanged in the market. More broadly, we continue to manage all costs tightly, working closely with our wholesale and supplier partners.' The company also released a new strategic plan on Thursday. Dubbed 'Levers For Growth,' Dr. Martens said that the plan builds on the work undertaken in fiscal 2025 to stabilize the business. The new plan focuses on four 'levers' including engaging more consumers, driving more product purchase occasions, curating market-right distribution, and simplifying the operating model. Dr. Martens said that the new strategy capitalizes on the strengths of its business, including its 'iconic global brand, high quality products, world-class supply chain, modern technology systems, committed wholesale and distributor partners and passionate and talented team,' and taps into the significant new markets and profit pools that are available to the company. Over the medium-term, Dr. Martens said it expects to deliver sustainable, profitable revenue growth above the rate of the relevant footwear market, with operating leverage driving a mid to high-teens EBIT margin and underpinned by strong cash generation. 'Levers For Growth will increase our opportunities by shifting the business from a channel-first to a consumer-first mindset,' Nwokorie said. 'We will give more people more reasons to buy more of our products, whether that's our iconic boots and shoes, newer product families such as Zebzag and Buzz, or adjacent categories such as sandals, bags and leather goods. And we will tailor distribution to each market, blending DTC and B2B, optimizing brand reach and ensuring a better use of capital.' The CEO added that he is 'laser focused' on day-to-day execution, managing costs and maintaining the company's operational discipline while it navigates the current macroeconomic uncertainties. Best of WWD All the Retailers That Nike Left and Then Went Back Mikey Madison's Elegant Red Carpet Shoe Style [PHOTOS] Julia Fox's Sleekest and Boldest Shoe Looks Over the Years [Photos] Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Watch: Shannon Smith samples chicken restaurants across the Triad
PIEDMONT TRIAD, N.C. (WGHP) — Chicken chains are flocking to the Piedmont Triad. Four new fast-casual franchises opened this spring in Guilford County alone, and more are under construction. People have packed Dave's Hot Chicken on Battleground Avenue in Greensboro. The Los Angeles-based chain serves huge tenders and sliders. Customers can choose their heat level, starting at no spice and running all the way up to reaper, which comes with a disclaimer. Just across the street on Lawndale Drive, A Hangry Joe's Hot Chicken is under construction, and one is already open on North Main Street in High Point. Their menu is inspired by Nashville's Famous Hot Chicken. Again, you can customize your spice levels. The hottest one requires you to sign a waiver to try it. Also in High Point, off NC 68/Eastchester Drive, Slim Chickens opened, serving a variety of all-natural fresh chicken tenders and wings with a selection of sauces and seasonings. Finally, a chicken restaurant with international flair. Pollo Compero is a chain started Guatemalan in 1971. They specialize in fried chicken, empanadas and other Latin-inspired side dishes. FOX8 FOODIE Shannon Smith took a tasting tour of the four new franchises and shares her thoughts. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
